Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective

Clinical Endocrinology

Volumn 68, Issue 3, 2008, Pages 343-349

  Bevan, J S ^a   Newell Price, J ^b   Wass, J A H ^c   Atkin, S L ^d   Bouloux, P M ^e   Chapman, J ^f   Davis, J R E ^g   Howlett, T A ^h   Randeva, H S ⁱ   Stewart, P M ^j   Viswanath, A ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d HULL ROYAL INFIRMARY   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^g MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^h LEICESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^j QUEEN ELIZABETH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LANREOTIDE AUTOGEL; LANTREOTIDE AUTOGEL; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FEMALE; HEALTH CARE PERSONNEL; HOME CARE; HUMAN; INJECTION; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HOME NURSING; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SELF CARE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 39149094648     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03044.x     Document Type: Article

References (8)

1. Caron, P., Bex, M., Cullen, D.R., Feldt-Rasmussen, U., Pico Alfonso, A.M., Pynka, S., Racz, K., Schopohl, J., Tabarin, A., Valimaki, M.J. Group for lanreotide Autogel long-term study on acromegaly 2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clinical Endocrinology, 60, 734 740.
2. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Laurberg, P., Pico, A.M., Valimaki, M. Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99 104.
3. Ciccarelli, A., Daly, A. Beckers, A. (2004) Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. Treatments in Endocrinology, 3, 77 81.
4. Ashwell, S.G., Bevan, J.S., Edwards, O.M., Harris, M.M., Holmes, C., Middleton, M.A. James, R.A. (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. European Journal of Endocrinology, 150, 473 480.
5. Alexopoulou, O., Abrams, P., Verhelst, J., Poppe, K., Velkeniers, B., Abstract, R. Maiter, D. (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. European Journal of Endocrinology, 151, 317 324.
6. van Thiel, S.W., Romijn, J.A., Biermasz, N.R., Ballieux, B.E., Frolich, M., Smit, J.W., Corssmit, E.P., Roalfsema, F. Pereira, A.M. (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology, 150, 489 495.
7. Gutt, B., Bidlingmaier, M., Kretschmar, K., Dieterle, C., Steffin, B. Schopohl, J. (2005) Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (Lanreotide Autogel). Experimental and Clinical Endocrinology and Diabetes, 113, 139 144.
8. Caron, P., Cogne, M., Raingeard, I., Bex-Bachellerie, V. Kuhn, J.M. (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clinical Endocrinology, 64, 209 214.